CHEMICAL & BIOMOLECULAR ENGINEERING
Published in Cancer Research (2021)
In this review, my colleagues and I review the landscape of using macrophages as anticancer treatments. In addition to highlighting efforts to alter the TME by targeting tumor-associated macrophages, we focus on approaches which directly engineer macrophages to perform anti-tumor functions. CAR macrophages, which was a previous paper, are discussed in depth and contrasted with CAR T cells for the treatment of solid tumors.
Find this paper on PubMed!
Published in Nature Biotechology (2020)
I was fortunate enough to be a co-author on this paper with the co-founder of Carisma Therapeutics, Mike Klichinsky. In this paper, we showed that macrophages could be transduced with a chimeric Ad5f35 adenovirus to express a first generation CAR. This CAR is active and causes the phagocytosis and killing of target postive tumor cells, while also stimulating pro-inflamatory cytokine release upon antigen stimulation. This promotes tumor clearance in vitro and in vivo, while also converting the TME from “cold” to “hot.”
Nicholas R. Anderson 